TY - JOUR
AU - Jørgensen, Morten Buus
AB - EDITORIAL Nephrol Dial Transplant , 2025, 40 , 617–620 https://doi.org/10.1093/ndt/gfae207 Advance access publication date: 20 September 2024 SELECT: a 10% reduction in body weight with GLP-1 receptor agonists improves kidney outcomes in overweight and obese patients without diabetes 1 2 3 Marieta Theodorakopoulou , Marius Miglinas and Morten Buus Jørgensen ; on behalf of the Diabesity Working Group which is an official body of the ERA (European Renal Association) First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece Nephrology Center, Santaros Klinikos, Medical Faculty, Vilnius University, Vilnius, Lithuania Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen, Denmark Correspondence to: Marieta Theodorakopoulou; E-mail: marietatheod@gmail.com Obesity is a major health problem worldwide and its prevalence is secondary analyses from cardiovascular outcome trials of GLP- expected to exceed 50% of the global population by 2035 [1 ]. Obese 1RAs in diabetic patients showed a significant improvement in the individuals have increased risk of multiple chronic diseases (e.g. composite kidney outcome [10 ]. More recently, the Evaluate Re- diabetes, cardiovascular disease, malignancies, etc.) leading to nal Function with Semaglutide Once Weekly (FLOW) trial demon- high cardiovascular and all-cause mortality rates [2 ]. Many stud- strated that semaglutide reduces the risk of 
TI - SELECT: a 10% reduction in body weight with GLP-1 receptor agonists improves kidney outcomes in overweight and obese patients without diabetes
JF - Nephrology Dialysis Transplantation
DO - 10.1093/ndt/gfae207
DA - 2024-09-20
UR - https://www.deepdyve.com/lp/oxford-university-press/select-a-10-reduction-in-body-weight-with-glp-1-receptor-agonists-IRuspA8qmM
SP - 617
EP - 620
VL - 40
IS - 4
DP - DeepDyve
ER -